CeriBell (NASDAQ:CBLL - Free Report) - William Blair lowered their FY2024 earnings per share (EPS) estimates for CeriBell in a research report issued on Wednesday, November 13th. William Blair analyst M. Andrew now expects that the company will post earnings per share of ($3.07) for the year, down from their prior forecast of ($0.99). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for CeriBell's current full-year earnings is ($2.11) per share. William Blair also issued estimates for CeriBell's Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.01) EPS.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million for the quarter, compared to analysts' expectations of $17.06 million.
A number of other equities analysts have also recently commented on the company. Canaccord Genuity Group assumed coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $30.00 target price for the company. TD Cowen began coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $31.00 target price for the company. JPMorgan Chase & Co. assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set an "overweight" rating and a $32.00 price objective on the stock. Canaccord Genuity Group raised their target price on shares of CeriBell from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Finally, Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a "buy" rating and a $32.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell presently has an average rating of "Buy" and an average target price of $31.20.
View Our Latest Analysis on CeriBell
CeriBell Price Performance
Shares of CBLL traded down $1.53 during midday trading on Monday, reaching $25.00. 118,871 shares of the stock were exchanged, compared to its average volume of 221,195. CeriBell has a 52 week low of $23.00 and a 52 week high of $29.53.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
